Nyhetsarkiv

13 Mars 2006 09:31
CHARISMA: NEW STUDY FURTHERS UNDERSTANDING OF THE ROLE OF DUAL ANTIPLATELET THERAPY IN THE PREVENTION OF ATHEROTHROMBOTIC EVENTS

Results from the CHARISMA trial showed that the combination of the antiplatelet agents clopidogrel and aspirin did not demonstrate a statistically significant reduction in the risk of heart attack, stroke or cardiovascular death compared to placebo and aspirin in a broad population of patients with either established atherothrombotic disease or multiple risk factors for atherothrombotic events.
1 Mars 2006 15:30
Apidra ® A New Rapid-Acting Insulin Analog is Now Available in the United States for Hyperglycemia in Adults with Type 2 and Type 1 Diabetes

New prandial insulin with the OptiClik® delivery system can work with longer-acting insulins, such as basal insulin Lantus®, providing a complementary approach to glucose control
1 Mars 2006 15:28
RESCHEDULING OF THE TRIAL DATE IN THE UNITED STATES PLAVIX® LITIGATION

At the request of Apotex and Dr Reddys Laboratories, citing scheduling conflicts for their legal counsels, the U.S. District Court for the Southern District of New York has rescheduled the trial date for the Plavix® patent litigation originally set for April 3, 2006.
15 Februari 2006 15:15
THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION PUBLISHES THE RIO-NORTH AMERICA STUDY

Paris, France, February 14, 2006 Sanofi-aventis announced that the results of the RIO North America trial were published today in The Journal of the American Medical Association (JAMA). The trial evaluated two-year treatment with rimonabant in overweight or obese patients, many of whom were at increased risk for diabetes and heart disease through the presence of additional risk factors.
6 Februari 2006 11:51
SANOFI PASTEUR DELIVERS MORE H5N1 VACCINE FOR U.S. GOVERNMENT PANDEMIC INITIATIVES

Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), has delivered more H5N1 vaccine to the U.S. government including investigational doses formulated with an adjuvant.
2 Februari 2006 16:35
Svenska Cardiologföreningen och sanofi-aventis stödjer forskning rörande prevention av hjärtkärlsjukdomar med utgångspunkt från kända kardiovaskulära och metabola riskfaktorer.

Svenska Cardiologföreningen och sanofi-aventis utlyser ett stipendium om 150 000 kronor inom området kardiometabol risk.
31 Januari 2006 13:40
MY CHILD MATTERS: LAUNCH OF A MOBILISATION CAMPAIGN AGAINST CHILDHOOD CANCER IN EMERGING COUNTRIES

The International Union against Cancer (UICC) and sanofi-aventis are launching a mobilisation program against childhood cancer in emerging countries, in preparation for World Cancer Day, February 4, 2006.
30 Januari 2006 16:28
Dynamic growth in 2005 full-year consolidated net sales: up 9.3% on a comparable basis1

Excellent performance from vaccines: up 26.9% on a comparable basis1 2005 adjusted earnings1 guidance raised Approval of Plavix® in Japan
24 Januari 2006 10:13
PLAVIX® APPROVED IN JAPAN

Paris - January 24, 2006 - Sanofi-aventis (EURONEXT : SAN and in New York NYSE : SNY) announced today that the antiplatelet agent Plavix® (clopidogrel) has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the reduction of recurrence after ischemic cerebrovascular disorder.
18 Januari 2006 13:42
FDA GRANTS PRIORITY REVIEW TO PLAVIXÒ (clopidogrel bisulfate) SUPPLEMENTAL NEW DRUG APPLICATION (sNDA) FOR ADDITIONAL TYPE OF HEART ATTACK

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental new drug application (sNDA) for the antiplatelet agent PLAVIX® (clopidogrel bisulfate) for treatment of patients with acute STsegment elevation myocardial infarction (STEMI).
13 Januari 2006 09:17
Pfizer to purchase sanofi-aventis rights to EXUBERAâ in application of change of control clauses

Sanofi-aventis announced today the signature of an agreement to transfer its rights to Exuberaâ, an inhaled human insulin, to Pfizer.
21 December 2005 08:58
SANOFI PASTEUR TO LICENSE MICRO-DELIVERY TECHNOLOGY

Lyon, France 21 December 2005 Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), has entered into an agreement with BD (Becton, Dickinson and Company) (NYSE: BDX) to license the Micro-Delivery technology of BD Medical-Pharmaceutical Systems for use in the administration of sanofi pasteurs human vaccine products. Läs resterande pressmeddelande i

Visa mer Loading...